An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help ...
I'm initiating SELLAS Life Sciences (SLS) with a "Hold" rating. The reason why I'm giving this biotech this rating is because it is in the process of developing its WT1-targeting immunotherapeutic ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
The alternative text for this image may have been generated using AI. For the launch of venetoclax in China in December 2020, the maximum follow-up duration was 48 months. Due to the relatively low ...
Patients were enrolled at the Peking University Institute of Hematology between July 2018 and November 2019. Human leukocyte antigen (HLA)-identical sibling donor (ISD) transplantation (6/6 matching ...
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
The open-label, single-arm trial studying Sellas’ small molecule met all primary endpoints. (iStock / Getty Images Plus) Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage ...
Kura Oncology ((KURA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results